pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
155
stories
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
Jun 8, 26
Tango data add to growing momentum for pancreatic cancer drugs
biopharma dive
Jun 8, 26
Incyte to buy blood disorder drug in possibly $2B deal
biopharma dive
Jun 5, 26
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
biopharma dive
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 3, 26
Bristol Myers turns focus to AI costs after broad rollout to workers
endpoints
Jun 3, 26
House bill aims to crack down on China biotech deals
biopharma dive
May 29, 26
Bristol Myers unveils data for one of its next-gen blood cancer drugs
biopharma dive
May 29, 26
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
biopharma dive
May 29, 26
#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successor
endpoints
May 29, 26
Pfizer, Innovent strike $10B cancer drug deal
biopharma dive
May 19, 26
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
stat
May 18, 26
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
stat
May 18, 26
Regeneron immunotherapy combo comes up short in melanoma trial
biopharma dive
May 12, 26
STAT+: Hims’ sales miss as telehealth competition grows
stat
May 12, 26
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
biopharma dive
May 12, 26
A year after Vertex’s big launch, pain drug research faces a pivotal moment
biopharma dive
May 12, 26
Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
endpoints
May 12, 26
STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
stat
May 8, 26
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
onclive
May 7, 26
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
onclive
May 6, 26
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
biopharma dive
May 5, 26
Cytokinetics heart drug scores in closely watched trial
biopharma dive
May 4, 26
UCB to acquire maker of antibody treatments for autoimmune diseases
stat
May 4, 26
UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
biopharma dive
May 1, 26
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
biopharma dive
Apr 30, 26
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
endpoints
Apr 30, 26
STAT+: Five-way obesity drug is super effective — in mice
stat
Apr 30, 26
Analysts focus on three programs in big year for Bristol Myers
endpoints
Apr 30, 26
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
biopharma dive
← prev
page 5 of 6
next →
